Mechanistic description
Partial metabolic interventions (e.g., mTOR inhibition alone) suppress SASP secretion but leave growth arrest intact because they fail to restore epigenetic architecture at senescence-associated heterochromatin foci (SAHF). Complete NAD+ restoration activates SIRT1, which deacetylates H3K9 and recruits SUV39H1/HP1 to re-establish heterochromatin, allowing silencing of p16INK4a and re-expression of E2F-target proliferation genes. This predicts that single-agent senolytics or mTOR inhibitors halt neurodegeneration-associated senescence progression, but combinatorial NAD+ boosting with SIRT1 activation achieves true reversal of established senescent phenotypes in neurons and glia.
Evidence for (5)
Regulation of SIRT1 and Its Roles in Inflammation.
SIRT1 and aging related signaling pathways.
CD38-NAD(+)-Sirt1 axis in T cell immunotherapy.
Novel Role of the SIRT1 in Endocrine and Metabolic Diseases.
Nutraceutical activation of Sirt1: a review.
Evidence against (2)
Nicotinamide riboside supplementation raises systemic NAD+ and shows cognitive benefits in mild cognitive impairment but does not demonstrate reversal of senescence biomarkers (p16, gamma-H2AX, SASP) in brain tissue, suggesting NAD+ restoration may attenuate rather than reverse neuronal senescence
SIRT1 activators reduce SASP and extend healthspan but comprehensive reviews confirm SIRT1 cannot fully reverse established growth arrest; H3K9me3 restoration at SAHFs requires cooperative epigenetic remodeling beyond SIRT1 activity alone
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 2 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.